List view / Grid view
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.
In this episode, we explore the current status and potential solutions to addressing major hurdles in oncology.
New understanding of the CRC and its interaction with STAT3 could lead to novel therapeutics and combination strategies.
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
New findings will enable the development of safer PARP inhibitors that inhibit PARP’s enzymatic activity without trapping it on DNA.
Researchers have discovered two distinct lineages of Fusobacterium nucleatum, which has great implications for colorectal cancer screening and therapeutics.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
Researchers have created a neutrophil therapy, involving micropatches that maintain the cells’ antitumour state, which could offer significant clinical and commercial value.
Despite significant strides in cancer research, metastasis remains the primary cause of cancer-related mortality globally. Joby Chesnick and Tracey Long, from the Digital Biology Group and Life Science Group, respectively, at BioRad Laboratories, reveal how investigation into circulating tumour cells (CTCs) and other rare cell types has led to the…
The Organoid Group have discovered a link between FBXW7 mutations and the EGFR signalling pathway, which could improve colorectal cancer treatments.
Inhibiting the LDHA and GOT1 enzymes could prevent cancer cells’ ability to produce energy, without affecting healthy cells.
An intravenous treatment to block lnc-HLX-2-7 from binding to the HLX promoter shrunk medulloblastoma tumours, prolonging survival in mice.
